iGRO™ is the only medical tool that gives evidence-based predictions for the first 12 months of growth hormone (GH) treatment, using pre-treatment data.


iGRO™ is an easy-to-use Software Medical Device, available in various countries (in Europe, Latin America and Asia).

iGRO™ is an easy-to-use, web-based tool. No software installation is required.

iGRO™ can be used on computers, laptops, tablets.

All iGRO™ output tables and graphs can be saved and printed.

iGRO™ applies evidence-based, validated and peer-reviewed growth prediction algorithm models, developed using clinical data in the KIGS database (the Pfizer International Growth Database), to provide realistic and personalised growth targets — helping you to assess and optimise response to growth hormone treatment.


database kigs


This international database contains growth data collected over a 25-year period from over 83,000 children who have received growth hormone treatment from 52 countries. These algorithms enable you to make a more accurate prediction, based on the gender, age and condition of a child; and monitor their response to treatment. Using this information you can identify any issues, confirm diagnoses and guide further treatment -offering personalised growth hormone treatment that is based on your patient’s needs.

iGRO™ is a web-based medical device tool that complies with all relevant European and local data protection regulations. It makes it easy to apply these algorithms in clinical practice — enabling physicians to predict how much a child may grow in the first and subsequent years of GH therapy.
It is designed to support physicians in calculating growth predictions for a range of pre-pubertal and pubertal patients, and provides evidence-based guidance and justification for GH treatment decisions.

iGRO™ can be used to calculate growth predictions for a range of patients.

For children with idiopathic growth hormone deficiency (IGHD)1 and children born small for gestational age (SGA):

  • Predictions for the first to 8th pre-pubertal year of treatment
  • Subsequent pre-pubertal years
  • Total pubertal growth.



Getting started is simple and all patient data is stored securely online. Standard baseline patient data can be entered before treatment begins and results are displayed in a clear, graphical format. iGRO™ enables you to make highly accurate growth predictions based on gender, age and condition of patients, and evaluate response after 12 months: helping you to manage patient expectations and optimise the treatment outcome.